Scleroderma

An in-depth report on the causes, diagnosis, and treatment of scleroderma.

I Would Like to Learn About:

Related Reports

References

Agarwal SK, Reveille JD. The genetics of scleroderma (systemic sclerosis). Curr Opin Rheumatol. 2010;22(2):133-138. PMID: 20090527 www.ncbi.nlm.nih.gov/pubmed/20090527.

Au K, Singh MK, Bodukam V, Bae S, et al. Atherosclerosis in systemic sclerosis: a systematic review and meta-analysis. Arthritis Rheum. 2011;63(7):2078-2090. PMID: 21480189 www.ncbi.nlm.nih.gov/pubmed/21480189.

Baron M, Bernier P, Côté LF, et al. Screening and therapy for malnutrition and related gastro-intestinal disorders in systemic sclerosis: recommendations of a North American expert panel. Clin Exp Rheumatol. 2010;28(2 Suppl 58):S42-S46. PMID: 20576213 www.ncbi.nlm.nih.gov/pubmed/20576213.

Bose N, Bena J, Chatterjee S. Evaluation of the effect of ambrisentan on digital microvascular flow in patients with systemic sclerosis using laser Doppler perfusion imaging: a 12-week randomized double-blind placebo controlled trial. Arthritis Res Ther. 2015;17:44. PMID: 25876611 www.ncbi.nlm.nih.gov/pubmed/25876611.

Burt RK, Shah SJ, Dill K, et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet. 2011;378(9790):498-506. PMID: 21777972 www.ncbi.nlm.nih.gov/pubmed/21777972.

Chin K, Channick RN. Pulmonary hypertension. In: Broaddus VC, Mason RJ, Ernst JD, et al, eds. Murray and Nadel's Textbook of Respiratory Medicine. 6th ed. Philadelphia, PA: Elsevier Saunders; 2016:chap 58.

Corte TJ, Du Bois RM, Wells AU. Connective tissue diseases. In: Broaddus VC, Mason RJ, Ernst JD, et al, eds. Murray and Nadel's Textbook of Respiratory Medicine. 6th ed. Philadelphia, PA: Elsevier Saunders; 2016:chap 65.

Daoussis D, Liossis SN, Tsamandas AC, et al. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford). 2010;49(2):271-280. PMID: 19447770 www.ncbi.nlm.nih.gov/pubmed/19447770.

Dospinescu P, Jones GT, Basu N. Environmental risk factors in systemic sclerosis. Curr Opin Rheumatol. 2013;25(2):179-183. PMID: 23287382 www.ncbi.nlm.nih.gov/pubmed/23287382.

Elhai M, Meune C, Avouac J, Kahan A, Allanore Y. Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford). 2012;51(6):1017-1026. PMID: 21900368 www.ncbi.nlm.nih.gov/pubmed/21900368.

Hugues, M, Herrick AL. Raynaud’s phenomenon. Best Pract Res Clin Rheumatol. 2016;30(1):112-132. PMID: 27421220 www.ncbi.nlm.nih.gov/pubmed/27421220.

Khanna D, Denton CP, Jahreis A, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet. 2016;387(10038):2630-2640. PMID: 27156934 www.ncbi.nlm.nih.gov/pubmed/27156934.

Khanna D, Denton CP, Merkel PA, et al. Effect of macitentan on the development of new ischemic digital ulcers in patients with systemic sclerosis: DUAL-1 and DUAL-2 randomized clinical trials. JAMA. 2016;315(18):1975-1988. PMID: 27163986 www.ncbi.nlm.nih.gov/pubmed/27163986.

Knobler R, Berlin G, Calzavara-Pinton P, et al. Guidelines on the use of extracorporeal photopheresis. J Eur Acad Dermatol Venereol. 2014;28 Suppl 1:1-37. PMID: 24354653 www.ncbi.nlm.nih.gov/pubmed/24354653.

Matucci-Cerinic M, Denton CP, Furst DE, et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2011;70(1):32-38. PMID: 20805294 www.ncbi.nlm.nih.gov/pubmed/20805294.

McMichael A, Curtis AR, Guzman-Sanchez D, Kelly AP. Folliculitis and other follicular disorders. In: Bolognia JL, Jorizzo JL, Schaffer JV, eds. Dermatology. 3rd ed. Philadelphia, PA: Elsevier; 2012:chap 38.

Nguyen VA, Eisendle K, Gruber I, Hugl B, Reider D, Reider N. Effect of the dual endothelin receptor antagonist bosentan on Raynaud's phenomenon secondary tosystemic sclerosis: a double-blind prospective, randomized, placebo-controlled pilot study. Rheumatology (Oxford). 2010;49(3):583-587. PMID: 20040526 www.ncbi.nlm.nih.gov/pubmed/20040526.

Onishi A, Sugiyama D, Kumagai S, Morinobu A. Cancer incidence in systemic sclerosis: meta-analysis of population-based cohort studies. Arthritis Rheum. 2013;65(7):1913-1921. PMID: 23576072 www.ncbi.nlm.nih.gov/pubmed/23576072.

Phumethum V, Jamal S, Johnson SR. Biologic therapy for systemic sclerosis: a systematic review. J Rheumatol. 2011;38(2):289-296.PMID: 21041277 www.ncbi.nlm.nih.gov/pubmed/21041277.

Schnitzer M. Hudson M, Baron M, Steele R; Canadian Scleroderma Research Group. Disability in systemic sclerosis - a longitudinal observational study. J Rheumatol. 2011;38(4):685-692. PMID: 21159826 www.ncbi.nlm.nih.gov/pubmed/21159826.

Tingey T, Shu J, Smuczek J, Pope J. Meta-analysis of healing and prevention of digital ulcers in systemic sclerosis. Arthritis Care Res (Hoboken). 2013;65(9):1460-1471. PMID: 23554239 www.ncbi.nlm.nih.gov/pubmed/23554239.

van Laar JM, Farge D, Sont JK, et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA. 2014;311(24):2490-2498. PMID: 25058083 www.ncbi.nlm.nih.gov/pubmed/25058083.

Varga J. Systemic sclerosis (scleroderma). In: Goldman L, Schafer AI, eds. Goldman-Cecil Medicine. 25th ed. Philadelphia, PA: Elsevier Saunders; 2016:chap 267.

Wigley FM, Boin F. Clinical features and treatment of scleroderma. In: Firestein GS, Budd RC, Gabriel SE, Mcinnes IB, O'Dell JR, eds. Kelley and Firestein's Textbook of Rheumatology. 10th ed. Philadelphia, PA: Elsevier; 2017:chap 84.

Zaghloul SS, Marraiki NAY, Goodfield MJD. Scleroderma. In: Lebwohl MG, Heymann WR, Berth-Jones J, Coulson I, eds. Treatment of Skin Disease: Comprehensive Therapeutic Strategies. 4th ed. Philadelphia, PA: Elsevier Saunders; 2014:chap 217.

BACK TO TOP

Review Date: 2/2/2017  

Reviewed By: Kevin Berman, MD, PhD, Atlanta Center for Dermatologic Disease, Atlanta, GA. Review provided by VeriMed Healthcare Network. Also reviewed by David Zieve, MD, MHA, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.

ADAM Quality Logo

A.D.A.M., Inc. is accredited by URAC, for Health Content Provider (www.urac.org). URAC's accreditation program is an independent audit to verify that A.D.A.M. follows rigorous standards of quality and accountability. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial policy, editorial process and privacy policy. A.D.A.M. is also a founding member of Hi-Ethics. This site complies with the HONcode standard for trustworthy health information: verify here.

The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. © 1997- 2019 A.D.A.M., a business unit of Ebix, Inc. Any duplication or distribution of the information contained herein is strictly prohibited.

A.D.A.M. content is best viewed in IE9 or above, Firefox and Google Chrome browser.